Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
William J. Febbo
AddedFeb 15, 2024
UpdatedMay 31, 2026
William J. Febbo

William J. Febbo

CEO, OptimizeRx

Crunchbase

William J. Febbo's Career

OptimizeRx
OptimizeRx

Rochester Hills, MI, US

CEO· C-Suite · Management
MedPanel
MedPanel

Cambridge, MA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

William J. Febbo's Career

OptimizeRx
OptimizeRx
Public$12M1002006Rochester Hills, MI, US
CEO· C-Suite · Management

Leadership at OptimizeRx

Gus D. HalasGus D. HalasBoard Member
Lynn O'Connor VosLynn O'Connor VosBoard Member
Jim LangJim LangBoard Member

Similar to OptimizeRx

RxAnteRxAntePortland, ME, USMedication Adherenceest. 2011RxAntePortland, ME, US · est. 2011

RxAnte Inc. develops advanced tech to enhance medication adherence, using analytics for targeted interventions.

Series B · $45.5M175
RxVantageRxVantageCulver City, CA, USHealthcare Software, Softwareest. 2008RxVantageCulver City, CA, US · est. 2008

RxVantage: Streamlining medical practices communication via efficient cloud-based software.

Series B · $2.8M143
Rx.HealthRx.HealthNew York City, NY, USest. 2016Rx.HealthNew York City, NY, US · est. 2016

Rx.Health offers a digital medicine platform for data collection, patient interaction, and streamlined workflows in the US.

Seed · $2.3M28
DecisionRxDecisionRxDover, DE, USHealthcare Servicesest. 2022DecisionRxDover, DE, US · est. 2022

DecisionRx: Tech-enabled healthcare service optimizing prescriptions for improved patient outcomes.

Late Stage Private · $100M11
MedPanel
MedPanel
Seed$155k1251999Cambridge, MA, US
Founder

Leadership at MedPanel

Janet BernardJanet BernardCEO

Similar to MedPanel

PanGenXPanGenXAuburndale, MA, USAnalytics, Medical Researchest. 2009PanGenXAuburndale, MA, US · est. 2009

PanGenX optimizes therapeutic care with innovative tools for advanced analytics on clinical and pharmacogenetic data.

Pre-Seed · $4.9M30
MarketResearch.comMarketResearch.comRockville, MD, USMarket Researchest. 1998MarketResearch.comRockville, MD, US · est. 1998

Marketresearch.com: Comprehensive market intelligence and research services provider in various sectors.

Public · $6M127
Pharma AnalyticsPharma AnalyticsAtlanta, GA, USMedical Analyticsest. 2016Pharma AnalyticsAtlanta, GA, US · est. 2016

Pharma Analytics Co. specializes in medical analytics.

Series A · $10M5
Formulary InsightsFormulary InsightsIndianapolis, IN, USAnalytics, Market Researchest. 2016Formulary InsightsIndianapolis, IN, US · est. 2016

Formulary Insights: Streamlining biopharma investment and marketing with predictive payer perceptions.

Seed · $1.7M14

William J. Febbo's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to William J. Febbo

Mark ThiererMark ThiererBoard Member · Discover Financial ServicesRinku PatelRinku PatelCEO · OptioRxMatthew RosenMatthew RosenCo-Founder · TraceRxBrad Van PeltBrad Van PeltCEO · Global Life Science VenturesRamy A MahmoudRamy A MahmoudBoard Member · OptinoseDan GittlemanDan GittlemanCo-Founder · Openpeak